Young at risk-people in Maputo City, Mozambique, present a high willingness to participate in HIV trials: Results from an HIV vaccine preparedness cohort study
Open Access
- 2 December 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (12) , e0260126
Abstract
Introduction: Vaccine efficacy testing requires engagement of willing volunteers with high disease incidence. We evaluated factors associated with willingness to participate in potential future HIV vaccine trials in Maputo, Mozambique.Methods: Adults aged 18–35 years without HIV and who reported at least two sexual partners in the 3 months prior to screening were enrolled into a 24-month observational study. They were asked at screening and exit if they would be willing to participate in a theoretical HIV vaccine study. Bivariate and multivariate logistic regression analyses were done between willingness to participate, demographic, sexual behavior, and motivational factors for screening visit data. Logistic regression with generalized estimating equations (GEE) was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for factors potentially associated with willingness to participate for data from both visits.Results: A total of 577 participants without HIV were eligible, including 275 (48%) women. The mean age was 22.2 (SD ± 3.9) years. At screening 529 (92%) expressed willingness to participate and the proportion remained stable at 378 (88%) of the 430 participants retained through the exit visit (p = 0.209). Helping the country (n = 556) and fear of needles (n = 26) were the top motive and barrier for willingness to participate, respectively. Results from the GEE binary logistic regression (screening visit and exit visit) showed that wanting to learn how to avoid risk behaviors (aOR 3.33, 95% CI: 1.61–6.86) and feeling protected against HIV infection (aOR 2.24, 95% CI: 1.07–4.7) were associated with willingness to participate in HIV vaccine studies.Conclusion: The majority of our study population in Mozambique expressed willingness to participate in a theoretical HIV vaccine trial. Participation in a HIV vaccine trial was seen as a way to contribute to the fight against HIV but was associated with some unrealistic expectations such as protection against HIV. This reinforces the need for continuous mobilization and awareness of potential participants to HIV vaccine trial.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
This publication has 33 references indexed in Scilit:
- HIV Related High Risk Behaviors and Willingness to Participate in HIV Vaccine Trials among China MSM by Computer Assisted Self-Interviewing SurveyBioMed Research International, 2013
- Age-dependent partnering and the HIV transmission chain: a microsimulation analysisJournal of The Royal Society Interface, 2013
- Willingness to Participate in HIV Vaccine Trials among Men Who Have Sex with Men in Chennai and Mumbai, India: A Social Ecological ApproachPLOS ONE, 2012
- Use of conjoint analysis to assess HIV vaccine acceptability: feasibility of an innovation in the assessment of consumer health-care preferencesInternational Journal of STD & AIDS, 2012
- A qualitative evaluation of volunteers' experiences in a phase I/II HIV vaccine trial in TanzaniaBMC Infectious Diseases, 2011
- Conceptual framework for behavioral and social science in HIV vaccine clinical researchVaccine, 2011
- Reasons for Declining to Enroll in a Phase I and II HIV Vaccine Trial after Randomization among Eligible Volunteers in Dar es Salaam, TanzaniaPLOS ONE, 2011
- The likelihood of participation in clinical trials can be measured: the Clinical Research Involvement ScalesJournal of Clinical Epidemiology, 2010
- Willingness to receive an HIV vaccine among incarcerated personsPreventive Medicine, 2006
- HIV Vaccine Trial Participation Among Ethnic Minority CommunitiesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006